Keerthana Rajendran

Ulcerative colitis (UC) is a chronic inflammatory bowel disease marked by persistent inflammation of the colon, mucosal ulceration which leads to disrupting the quality of life. Traditional therapies often introduced new risks including bradycardia, macular edema and other metabolic complications highlighting the need for new targeted interventions. Guselkumab, is a monoclonal antibody which was designed to block interleukin-22 (IL-22) driven inflammatory signaling, provides more precise...

Non–small cell lung cancer (NSCLC) is one of the most challenging cancers to treat, especially the KRAS G12C mutation which historically known as undruggable target. In this case, Sotorasib has changed this by showing inhibition against the KRAS G12C mutant protein and making it to stay in an inactive GDP-bound state. This action shuts down downstream MAPK signaling which helps in slowing tumor cell proliferation and activation of apoptosis. Preclinical development of sotorasib involved a set...

Metabolic dysfunction–associated steatohepatitis (MASH) has a long history of therapeutic challenge due hepatic fat accumulation, inflammation and progressive fibrosis. Traditional drug candidates introduced many new problems such as hypoglycemia, LDL elevation and complex drug–drug interactions lead to limiting long term safety use. Resmetirom, a selective thyroid hormone receptor beta (THR-β) agonist has directly enhanced liver specific lipid metabolism without causing any thyroid hormone...